An NF-κB- and Therapy-Related Regulatory Network in Glioma: A Potential Mechanism of Action for Natural Antiglioma Agents.
CD markers
NF-κB
anticancer therapy
glioma
natural antiglioma agents
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
19 Apr 2022
19 Apr 2022
Historique:
received:
02
04
2022
revised:
14
04
2022
accepted:
17
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
High-grade gliomas are among the most aggressive malignancies, with significantly low median survival. Recent experimental research in the field has highlighted the importance of natural substances as possible antiglioma agents, also known for their antioxidant and anti-inflammatory action. We have previously shown that natural substances target several surface cluster of differentiation (CD) markers in glioma cells, as part of their mechanism of action. We analyzed the genome-wide NF-κB binding sites residing in consensus regulatory elements, based on ENCODE data. We found that NF-κB binding sites reside adjacent to the promoter regions of genes encoding CD markers targeted by antiglioma agents (namely, CD15/FUT4, CD28, CD44, CD58, CD61/SELL, CD71/TFRC, and CD122/IL2RB). Network and pathway analysis revealed that the markers are associated with a core network of genes that, altogether, participate in processes that associate tumorigenesis with inflammation and immune evasion. Our results reveal a core regulatory network that can be targeted in glioblastoma, with apparent implications in individuals that suffer from this devastating malignancy.
Identifiants
pubmed: 35625673
pii: biomedicines10050935
doi: 10.3390/biomedicines10050935
pmc: PMC9138293
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Neurooncol. 2017 May;132(3):373-381
pubmed: 28365838
Nature. 2012 Sep 6;489(7414):91-100
pubmed: 22955619
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
pubmed: 20576703
Genes (Basel). 2018 Jan 09;9(1):
pubmed: 29315242
Int J Biochem Cell Biol. 2018 Jan;94:79-88
pubmed: 29208566
Oncol Rep. 2010 Mar;23(3):725-32
pubmed: 20127012
Biosci Rep. 2018 Jun 12;38(3):
pubmed: 29555826
J Neurooncol. 2003 Oct;65(1):3-13
pubmed: 14649881
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD007415
pubmed: 23633341
Am J Cancer Res. 2018 Jun 01;8(6):916-931
pubmed: 30034931
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
J Cell Physiol. 2010 Nov;225(3):682-91
pubmed: 20509143
Genome Res. 2012 Sep;22(9):1798-812
pubmed: 22955990
Nucleic Acids Res. 2011 May;39(9):3892-902
pubmed: 21245048
Tumour Biol. 2017 May;39(5):1010428317705744
pubmed: 28475011
Front Biosci. 2006 May 01;11:1607-19
pubmed: 16368541
Curr Opin Neurol. 2008 Dec;21(6):720-7
pubmed: 18989119
Eur Rev Med Pharmacol Sci. 2014 Aug;18(16):2349-56
pubmed: 25219837
Methods Protoc. 2021 Jan 26;4(1):
pubmed: 33530325
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Nucleic Acids Res. 2011 Jan;39(Database issue):D876-82
pubmed: 20959295
Cancer Res. 2010 Mar 15;70(6):2455-64
pubmed: 20197461
Cancers (Basel). 2020 Sep 10;12(9):
pubmed: 32927726
J Inflamm Res. 2021 Mar 25;14:1069-1084
pubmed: 33790621
Alkaloids Chem Biol. 2018;79:139-189
pubmed: 29455835
Genome Res. 2012 Sep;22(9):1813-31
pubmed: 22955991
Oncotarget. 2011 Aug;2(8):646-53
pubmed: 21896960
Oncogene. 2012 Mar 15;31(11):1468-74
pubmed: 21822306
Nat Prod Res. 2017 May;31(10):1195-1200
pubmed: 27609488
Biochem Pharmacol. 2011 Mar 1;81(5):606-16
pubmed: 21182827
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Immunol Lett. 2011 Mar 30;135(1-2):1-9
pubmed: 20863851
J Interferon Cytokine Res. 1998 Jun;18(6):423-8
pubmed: 9660250
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D493-6
pubmed: 14681465
J Neurooncol. 2007 Oct;85(1):39-47
pubmed: 17479228
Nature. 2020 Jul;583(7818):699-710
pubmed: 32728249
J Neurooncol. 2015 Jun;123(2):217-24
pubmed: 25935110
Front Cell Dev Biol. 2021 Sep 17;9:730726
pubmed: 34604232
Glycobiology. 2017 Nov 1;27(11):999-1005
pubmed: 28973293
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
J Clin Oncol. 2010 May 10;28(14):2467-74
pubmed: 20368557
Front Immunol. 2020 Dec 10;11:598444
pubmed: 33362782
Transl Oncol. 2009 Dec;2(4):247-57
pubmed: 19956386
Mol Syst Biol. 2017 Dec 1;13(12):956
pubmed: 29196508
J Neuroinflammation. 2009 Mar 09;6:8
pubmed: 19272160
J Immunol. 2000 Sep 1;165(5):2665-70
pubmed: 10946296
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Cancer Res. 2006 Feb 1;66(3):1536-42
pubmed: 16452210
Anal Bioanal Chem. 2018 Jan;410(3):1071-1077
pubmed: 29046922
BMC Cancer. 2012 Sep 11;12:406
pubmed: 22967049
Nucleic Acids Res. 2019 Jan 8;47(D1):D853-D858
pubmed: 30407534
Cancer Cell. 2009 Feb 3;15(2):135-47
pubmed: 19185848
Virology. 2021 Nov;563:74-81
pubmed: 34478955
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
Cell Death Dis. 2017 Aug 3;8(8):e2968
pubmed: 28771224
Tumour Biol. 2013 Aug;34(4):1991-2002
pubmed: 23625692
Nat Prod Res. 2022 Feb 19;:1-8
pubmed: 35184636
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
PLoS One. 2013;8(1):e55527
pubmed: 23383216
Br J Nutr. 2009 Jul;102(2):264-72
pubmed: 19222875
Cells. 2019 Sep 25;8(10):
pubmed: 31557902
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Stem Cells. 2009 Dec;27(12):2928-40
pubmed: 19725119
Biochem Biophys Res Commun. 2013 Jan 4;430(1):436-41
pubmed: 23178569
Nucleic Acids Res. 2013 Jan;41(Database issue):D171-6
pubmed: 23203885
Mol Cell Biol. 1997 May;17(5):2605-14
pubmed: 9111330
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Acta Neuropathol. 1997 Sep;94(3):216-25
pubmed: 9292690
Exp Cell Res. 2001 May 1;265(2):221-33
pubmed: 11302687
Oncotarget. 2016 May 31;7(22):33440-50
pubmed: 26967052
Cytokine. 2015 Sep;75(1):197-206
pubmed: 25934648
Anticancer Agents Med Chem. 2020;20(1):103-110
pubmed: 31755397